What's Going On With Longevity Health Shares Monday?

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

What's Going On With Longevity Health Shares Monday?

, Benzinga - 2:39 PM ET 4/14/2025 default

Longevity Health Holdings, Inc. ( XAGE ) (NASDAQ:XAGE shares are soaring on Monday after the company announced it entered into a merger agreement with 20/20 BioLabs, Inc., a provider of testing for the early detection and management of chronic disease.

The Details: The deal, which follows Longevity's January acquisition of Elevai Skincare, aligns with the company's strategy to expand into diagnostics to build synergies with its existing bio-aesthetics portfolio, as well as its contemplated expansion into nutrition.

20/20 BioLabs offers OneTest, a multi-cancer early detection blood test, and is preparing to launch a new “longevity test” that analyzes biomarkers tied to aging and chronic disease. The combined company anticipates over $1 million in operational savings and potential cross-selling across both customer bases.

The merger is expected to double Longevity’s fiscal-year 2025 anticipated revenue from approximately $3-4 million to approximately $7-8 million.

The merger is expected to close in the third quarter of 2025, subject to shareholder approval and other customary closing conditions.

See Also: Crude Oil Moves Lower; M&T Bank Earnings Miss Views

XAGE Price Action: At the time of publication, Longevity shares are trading 51.7% higher at 19 cents, according to data from Benzinga Pro.

Image: via Shutterstock